130 related articles for article (PubMed ID: 34115902)
21. The Protective Mechanism of Afuresertib against Esophageal Cancer.
Min B; Wang Y; Liang F; Wang CX; Wang F; Yang Z
Dis Markers; 2022; 2022():1832241. PubMed ID: 35872696
[TBL] [Abstract][Full Text] [Related]
22. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
23. Merkel cell carcinoma.
Wallis S; Durham-Hall A; Tandon N; Brotherston TM; Shrestha BM
JNMA J Nepal Med Assoc; 2010; 49(178):151-4. PubMed ID: 21485603
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
25. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
[TBL] [Abstract][Full Text] [Related]
27. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
28. Akt and mTOR mediate programmed necrosis in neurons.
Liu Q; Qiu J; Liang M; Golinski J; van Leyen K; Jung JE; You Z; Lo EH; Degterev A; Whalen MJ
Cell Death Dis; 2014 Feb; 5(2):e1084. PubMed ID: 24577082
[TBL] [Abstract][Full Text] [Related]
29. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
30. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.
Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S
Cells; 2019 Jul; 8(8):. PubMed ID: 31370278
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
32. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
J Mol Med (Berl); 1999 Nov; 77(11):792-7. PubMed ID: 10619439
[TBL] [Abstract][Full Text] [Related]
33. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death.
Makhov P; Golovine K; Teper E; Kutikov A; Mehrazin R; Corcoran A; Tulin A; Uzzo RG; Kolenko VM
Br J Cancer; 2014 Feb; 110(4):899-907. PubMed ID: 24434432
[TBL] [Abstract][Full Text] [Related]
34. Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation.
Huang C; Sheng S; Li R; Sun X; Liu J; Huang G
Oncol Rep; 2015 Feb; 33(2):875-84. PubMed ID: 25484022
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma.
Tucci MG; Lucarini G; Giangiacomi M; Zizzi A; Criante P; Ricotti G; Biagini G
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1220-5. PubMed ID: 17062035
[TBL] [Abstract][Full Text] [Related]
36. Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma.
Temblador A; Topalis D; Andrei G; Snoeck R
Tumour Virus Res; 2022 Dec; 14():200244. PubMed ID: 36007768
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
[TBL] [Abstract][Full Text] [Related]
39. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
40. Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells.
Rao YK; Wu AT; Geethangili M; Huang MT; Chao WJ; Wu CH; Deng WP; Yeh CT; Tzeng YM
Chem Res Toxicol; 2011 Feb; 24(2):238-45. PubMed ID: 21158420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
